CareDx (NASDAQ:CDNA) Earns Overweight Rating from Stephens

Stephens restated their overweight rating on shares of CareDx (NASDAQ:CDNA) in a research report sent to investors on Thursday,Benzinga reports. The firm currently has a $40.00 price target on the stock.

Several other brokerages have also commented on CDNA. StockNews.com upgraded CareDx from a “hold” rating to a “buy” rating in a report on Wednesday. BTIG Research decreased their price objective on CareDx from $40.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday, November 5th. HC Wainwright reiterated a “neutral” rating and set a $26.00 price objective on shares of CareDx in a report on Tuesday, January 14th. Finally, Wells Fargo & Company upgraded CareDx from an “underweight” rating to an “equal weight” rating and decreased their price objective for the company from $28.00 to $24.00 in a report on Wednesday, January 15th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, CareDx presently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

CareDx Stock Up 5.2 %

CareDx stock opened at $22.15 on Thursday. The business has a fifty day moving average of $22.69 and a two-hundred day moving average of $25.23. The firm has a market cap of $1.19 billion, a P/E ratio of -8.20 and a beta of 1.87. CareDx has a twelve month low of $7.42 and a twelve month high of $34.84.

CareDx (NASDAQ:CDNA) last issued its quarterly earnings data on Wednesday, February 26th. The company reported $1.51 EPS for the quarter, beating the consensus estimate of $0.05 by $1.46. CareDx had a negative return on equity of 53.70% and a negative net margin of 45.90%. The firm had revenue of $86.58 million during the quarter, compared to analyst estimates of $84.56 million. Equities analysts expect that CareDx will post -0.9 earnings per share for the current year.

Hedge Funds Weigh In On CareDx

Hedge funds have recently made changes to their positions in the company. Quarry LP acquired a new position in shares of CareDx in the 3rd quarter valued at $27,000. Sterling Capital Management LLC grew its position in CareDx by 771.2% during the 4th quarter. Sterling Capital Management LLC now owns 1,272 shares of the company’s stock worth $27,000 after purchasing an additional 1,126 shares during the period. Harvest Fund Management Co. Ltd acquired a new stake in CareDx during the 3rd quarter worth about $52,000. KBC Group NV acquired a new stake in CareDx during the 3rd quarter worth about $99,000. Finally, Tower Research Capital LLC TRC grew its position in CareDx by 553.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,922 shares of the company’s stock worth $84,000 after purchasing an additional 3,322 shares during the period.

CareDx Company Profile

CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients.